For cancer gene therapy, replicative adenovirus is a promising vector to overcome low infectivity and poor gene delivery of nonreplicative adenovirus in vivo, but its therapeutic efficacy is still unsatisfactory because of the limited spread of replicative virus in a solid tumor. Therefore, the combined therapy with other antitumor agents may be necessary. Nonreplicative adenovirus expressing a therapeutic gene may be a promising candidate because E1 proteins expressed by replicative adenovirus would render nonreplicative adenovirus replicative, augmenting a transgene expression. In this study, we first found that mouse hepatoma Hepa 1-6 cells were permissive for the replication and cytopathic effect of human adenovirus, which enabled us to examine the potential of combined replicative adenovirus and nonreplicative adenovirus expressing an immunostimulator in an immunocompetent mouse-syngeneic Hepa 1-6 tumor model. Nonreplicative adenovirus expressing interleukin-12 (AdIL-12) was used as a model. In vitro coinfection of two adenoviruses produced higher concentrations of IL-12 than infection of AdIL-12 alone in this cell line. In vivo experiments with Hepa 1-6 tumors in syngeneic immunocompetent C57BL/6 mice showed higher concentrations of serum IL-12 and greater therapeutic efficacy in the combination therapy than infection of either adenovirus. These data indicate that the combination of replicative adenovirus and nonreplicative adenovirus expressing an immunostimulator appears to be very efficacious for cancer gene therapy.
Recombinant adenovirus is being widely used as a vehicle for gene delivery in cancer gene therapy. In vivo therapeutic efficacy of nonreplicative adenovirus is however limited mainly because of its low infectivity and poor gene delivery to a solid tumor. 1 Use of replicative adenovirus may be a potential candidate to overcome this issue. 1, 2 ONYX-015 is such an adenovirus with a deletion in E1B 55 kDa gene and reportedly replicates selectively in the cells defective in p53 gene. 3 Despite the initial expectation from the preclinical data with animal models, the antitumor effect of ONYX-015 as a single agent is minimal in head and neck cancers despite repeated daily injection, and no obvious response is observed in pancreatic, colorectal or ovarian carcinomas in clinical trials. 1, 2, 4, 5 One of the reasons is thought to be the limited in vivo spread of the replicative virus in a solid tumor despite rapid spread in an in vitro cell culture system.
Hence multimodality treatments with other antitumor agents, which ideally exhibit no crossresistance and synergize with oncolytic adenovirus, have employed to improve the therapeutic efficacy of replicative adenovirus. The potentially synergistic interaction of replicative adenovirus with chemotherapy or radiotherapy has been demonstrated in several animal models and clinical trials. 2, 4, 5 The combination with nonreplicative adenovirus expressing a transgene may also be promising because E1 proteins expressed by replicative adenovirus would render nonreplicative adenovirus replicative, thereby augmenting a transgene expression. Indeed, the enhanced efficacy of suicide gene therapy by replicative adenovirus has been demonstrated in animal models. 4, 5 Although we have been interested in nonreplicative adenovirus expressing an immunostimulator as a candidate for combination, this type of study has been limited owing to the lack of a relevant immunocompetent animal model. Antitumor effect and safety issue of replicative adenovirus have all been studied in immunodeficient mouse-human xenograft models, because replication of human adenovirus that is used to construct recombinant adenovirus vectors is reportedly restricted to human cells. 4 In this article, we first evaluated the replication of human replicative adenovirus in several rodent tumor cells. The replicative adenovirus we used has previously been constructed in our lab in which E1A and E1B 19 K proteins were expressed from CAG and CMV promoters, respectively, and E1B 55 K and E3 genes were deleted (formerly AdCALE1AL; we call it AdREP hereafter). 6 We found that Hepa 1-6 cells (a poorly immunogenic mouse hepatoma cell line derived from C57BL/6 mice) (ATCC, Manassa, VA, USA) 7 is highly sensitive to adenovirus infection and susceptible to viral replication, progeny production and cytopathic effect (CPE), although slightly less permissive as compared to a human hepatoma cell line HuH-7 as a control. Thus, more than 95% of Hepa 1-6 and HuH-7 cells were stained with x-gal when infected with adenovirus expressing b-galactosidase (AdLacZ) 6 at a multiplicity of infection (MOI) of 10 and 3, respectively (data not shown). In addition, infection of AdREP efficiently induced CPE (ie, cell ballooning) in both cells in dose-and time-dependent manners ( Figure 1 ). For example, infection of AdREP at an MOI of 1 induced more than 95% of cell death in Hepa 1-6 and HuH-7 cells in 10-12 days. Infection of AdLacZ (as a negative control) at MOIs of up to 30 did not affect cell viability (data not shown). Efficient progeny production following AdREP infection, a most relevant marker for oncolytic virus, was also confirmed in Hepa 1-6 cells, although the levels were lower than those in HuH-7 cells ( Figure 2 ). These results demonstrate the relatively high infectivity, replication and CPE of human adenovirus in mouse Hepa 1-6 cells, although we cannot completely exclude the possibility that the cytocidal effect of E1A protein overexpressed from a strong viral promoter may partly contribute to cell death. This cell line thus enabled us to study the feasibility of the combined therapy of replicative adenovirus and nonreplicative adenovirus expressing an immunostimulator.
Nonreplicative adenovirus expressing mouse interleukin-12 (AdIL-12) was used as a model in this study. IL-12 is reported to exhibit a potent antitumor effect by promoting NK cell activity and Th1 immune response. 8, 9 Coinfection of AdREP and AdIL-12 into Hepa 1-6 and HuH-7 cells in vitro produced B8-fold and B15-fold, respectively, higher IL-12 than AdIL-12 alone (Figure 3a) . Higher copy number of AdIL-12 vector in the cells infected with both adenoviruses than those with AdIL-12 alone was also demonstrated by polymerase chain reaction (PCR) analysis (Figure 3a) . Thus, E1A proteins expressed by AdREP did render nonreplicative AdIL-12 replicative. In in vivo experiments with immunocompetent C57BL/6 mice bearing Hepa 1-6 tumors, intratumoral injection of AdREP, AdIL-12, or both, significantly suppressed tumor growth as compared to that of AdLacZ ( Figure 4) . The efficacy was the highest in the combined therapy, followed by AdREP alone and AdIL-12 alone. In addition, only the combined therapy induced complete tumor regression in three out of 10 (30%) mice. Indeed, serum concentrations of IL-12 in mice received intratumoral injection of AdREP and AdIL-12 were B3-fold higher than those of AdIL-12 alone 24 h after injection (Figure 3b) . These data clearly demonstrate the enhanced effect of the combined AdREP and AdIL-12. However, the tumors, which were treated with AdREP or AdREP and AdIL-12 and did not completely regressed, started to regrow B2 weeks after injection (data not shown).
Replication of human adenovirus is generally poor in nonhuman cells. However, we found in this study that mouse Hepa 1-6 cells can support replication and progeny production of human adenovirus. A few other cell lines of mouse and hamster origin have also been previously identified to be permissive for human adenovirus replication. 10, 11 Our finding allowed us to evaluate the therapeutic efficacy of the combined replicative adenovirus and nonreplicative adenovirus expressing an immunostimulator (IL-12 in this study) in immunocompetent mice. To our knowledge, this is the Replicative adenovirus and immunogene therapy Y Nagayama et al first report demonstrating that the combination of replicative adenovirus and nonreplicative adenovirus expressing IL-12 produced higher IL-12 in vitro and in vivo, and augmented the therapeutic efficacy as compared with either adenovirus in immunocompetent mice. The efficacy of the combination of replicative adenovirus and nonreplicative adenovirus expressing IL-2 has previously been demonstrated in immunodeficient mice. 12 Taken together, these results clearly indicate that nonreplicative adenovirus encoding an immunostimulator can be a good candidate for the combination therapy with replicative adenovirus.
Both replicative adenovirus therapy and immunogene therapy have shown somewhat limited therapeutic effects as a single agent. 4, 5, 13 By combining these two approaches, replicative adenovirus would provide an environment rich in tumor antigens by killing cancer cells, where immune cells recruited and activated by an immunostimulator expressed would elicit immune response against these tumor antigens. Moreover, expression level of an immunostimulator can be augmented by replication of nonreplicative adenovirus. Indeed, antitumor effects of most of cytokines are positively correlated with their expression levels. 13 Combination of replicative adenovirus and nonreplicative adenovirus expressing an immunostimulator is therefore highly rationale. Enhanced therapeutic efficacy of replicative herpes simplex virus encoding IL-12 has also been reported in immunocompetent mice. [14] [15] [16] Finally, combination of replicative adenovirus and nonreplicative adenovirus encoding an immunostimulator described in this article is a promising approach for cancer gene therapy. However, a single replicative adenovirus armed with an immunostimulator will be more efficacious, because the need of double infection curtails the therapeutic efficacy when MOI is low or tumor cells are resistant to adenovirus infection. Replicative adenovirus and immunogene therapy Y Nagayama et al
